Debt to Equity Ratio Chart

View Debt to Equity Ratio for LSTA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 0.00
September 30, 2025 0.00
June 30, 2025 0.0022
March 31, 2025 0.0036
December 31, 2024 0.0046
September 30, 2024 0.0054
June 30, 2024 0.0058
March 31, 2024 0.0061
December 31, 2023 0.0063
September 30, 2023 0.0065
June 30, 2023 0.0066
March 31, 2023 0.0069
December 31, 2022 0.0073
September 30, 2022 0.0076
June 30, 2022 0.0068
March 31, 2022 0.0071
December 31, 2021 0.0077
September 30, 2021 0.0035
June 30, 2021 0.0042
March 31, 2021 0.0049
December 31, 2020 0.0192
September 30, 2020 0.0188
June 30, 2020 0.0235
Date Value
March 31, 2020 0.0507
December 31, 2019 0.047
September 30, 2019 0.0427
June 30, 2019 0.0128
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.0005
March 31, 2018 0.002
December 31, 2017 0.0032
September 30, 2017 0.0067
June 30, 2017 0.0193
March 31, 2017 -7.743
December 31, 2016 0.2625
September 30, 2016 0.6162
June 30, 2016 1.650
March 31, 2016 0.3164
December 31, 2015 0.7074
September 30, 2015 0.3036
June 30, 2015 0.2582
March 31, 2015 0.3318
December 31, 2014 0.2844
September 30, 2014 0.2691
June 30, 2014 0.0633
March 31, 2014 0.082

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.0565
Alnylam Pharmaceuticals, Inc. 2.206
Anika Therapeutics, Inc. 0.1839
Savara, Inc. 0.2117
Vericel Corp. 0.2556